Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML
Articolo
Data di Pubblicazione:
2020
Citazione:
Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML / Lonetti, A; Indio, V; Laginestra, Ma; Tarantino, G; Chiarini, F; Astolfi, A; Bertuccio, Sn; Martelli, Am; Locatelli, F; Pession, A; Masetti, R. - In: CANCERS. - ISSN 2072-6694. - 12:7(2020), pp. 1-18. [10.3390/cancers12071972]
Tipologia CRIS:
Articolo su rivista
Keywords:
BRAF; ChIP-seq; DOT1L; Pediatric acute myeloid leukemia; Pinometostat; Sorafenib; Targeted therapy;
Elenco autori:
Lonetti, A; Indio, V; Laginestra, Ma; Tarantino, G; Chiarini, F; Astolfi, A; Bertuccio, Sn; Martelli, Am; Locatelli, F; Pession, A; Masetti, R
Link alla scheda completa:
Link al Full Text:
Pubblicato in: